Zura Bio Limited (NASDAQ:ZURA) Short Interest Update

Zura Bio Limited (NASDAQ:ZURA) was the target of a significant growth in short interest in the month of January. As of January 30th, there was short interest totaling 3,847,872 shares, a growth of 27.7% from the January 15th total of 3,012,119 shares. Based on an average daily trading volume, of 1,149,960 shares, the short-interest ratio is presently 3.3 days. Currently, 7.6% of the shares of the company are sold short. Currently, 7.6% of the shares of the company are sold short. Based on an average daily trading volume, of 1,149,960 shares, the short-interest ratio is presently 3.3 days.

Zura Bio Stock Performance

Shares of NASDAQ ZURA opened at $6.11 on Wednesday. The firm has a market cap of $397.27 million, a P/E ratio of -9.40 and a beta of 0.21. Zura Bio has a 1 year low of $0.97 and a 1 year high of $6.88. The firm’s 50 day moving average price is $5.29 and its 200 day moving average price is $3.80.

Hedge Funds Weigh In On Zura Bio

Several large investors have recently added to or reduced their stakes in ZURA. VR Adviser LLC boosted its stake in Zura Bio by 15.4% in the 4th quarter. VR Adviser LLC now owns 5,345,115 shares of the company’s stock worth $28,008,000 after buying an additional 713,899 shares during the last quarter. Braidwell LP boosted its position in shares of Zura Bio by 28.6% in the fourth quarter. Braidwell LP now owns 3,180,389 shares of the company’s stock worth $16,665,000 after acquiring an additional 707,583 shares during the last quarter. Jump Financial LLC purchased a new stake in Zura Bio in the fourth quarter valued at approximately $407,000. ExodusPoint Capital Management LP acquired a new position in Zura Bio during the fourth quarter worth approximately $246,000. Finally, Squarepoint Ops LLC raised its stake in Zura Bio by 34.6% during the fourth quarter. Squarepoint Ops LLC now owns 33,801 shares of the company’s stock worth $177,000 after purchasing an additional 8,680 shares during the period. 61.14% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ZURA has been the subject of several recent analyst reports. Wall Street Zen cut shares of Zura Bio from a “hold” rating to a “sell” rating in a research note on Sunday, November 16th. Chardan Capital reaffirmed a “buy” rating and set a $10.00 price objective on shares of Zura Bio in a report on Friday, November 14th. Leerink Partners raised Zura Bio to a “strong-buy” rating in a report on Sunday, November 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a research note on Friday, January 9th. Finally, Wedbush began coverage on shares of Zura Bio in a research report on Monday, February 9th. They issued an “outperform” rating and a $15.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Zura Bio presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.60.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.